EV 68228 N
Alternative Names: Enterovirus D68-specific monoclonal antibody - KBio; EV68-228-N; EVD68-228N; KB-13-ALatest Information Update: 28 Apr 2025
At a glance
- Originator KBio
- Developer KBio; National Institute of Allergy and Infectious Diseases
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Enterovirus infections
- Preclinical Acute flaccid myelitis
Most Recent Events
- 19 Mar 2025 National Institute of Allergy and Infectious Diseases completes a phase I trial in Enterovirus infections (In volunteers) in USA (IV) (NCT06444048
- 28 Jun 2024 US FDA approves IND application for EV 68228 N in Acute flaccid myelitis
- 11 Jun 2024 Phase-I clinical trials in Enterovirus infections (In volunteers) in USA (IV) (NCT06444048)